Hepatitis C and renal disease: an update (Q35547800)

8 August 2017

1 reference

title

Hepatitis C and renal disease: an update (English)

1 reference

8 August 2017

1 reference

1 reference

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(03)00828-X

16 March 2024

author name string

Catherine M. Meyers

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14520615

16 March 2024

Leonard B. Seeff

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14520615

16 March 2024

Catherine O. Stehman-Breen

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14520615

16 March 2024

Jay H. Hoofnagle

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14520615

16 March 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14520615

16 March 2024

publication date

1 October 2003

1 reference

full work available at URL

8 August 2017

https://api.elsevier.com/content/article/PII:S027263860300828X?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(03)00828-X

https://api.elsevier.com/content/article/PII:S027263860300828X?httpAccept=text/plain

16 March 2024

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(03)00828-X

American Journal of Kidney Diseases

16 March 2024

published in

1 reference

8 August 2017

42

1 reference

8 August 2017

631-657

1 reference

8 August 2017

4

1 reference

Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line

8 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Efficient initiation of HCV RNA replication in cell culture

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Long-term follow-up of chimpanzees inoculated with the first infectious clone for hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Vaccination of chimpanzees against infection by the hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in germany: a 20-year multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

The natural history of hepatitis C virus infection: host, viral, and environmental factors

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Clinical outcomes after transfusion-associated hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

45-year follow-up of hepatitis C virus infection in healthy young adults

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

10-Year follow-up after interferon-alpha therapy for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Peginterferon alfa-2a in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

A role for hepatitis C virus infection in type II cryoglobulinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Oligoclonal non-neoplastic B cell expansion is the key feature of type II mixed cryoglobulinemia: Clinical and molecular findings do not support a bone marrow pathologic diagnosis of indolent B cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Membranoproliferative glomerulonephritis associated with hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Renal involvement in hepatitis C infection: cryoglobulinemic glomerulonephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Hepatitis C virus infection and renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Glomerular disease associated with hepatitis C virus infection in native kidneys

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Hepatitis C virus infection and acute or chronic glomerulonephritis: an epidemiological and clinical appraisal

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Renal disease associated with hepatitis C infection after kidney and liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Mixed cryoglobulinaemia after hepatitis C virus: more and less ambiguity

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Prevalence of hepatitis C in patients with idiopathic glomerulopathies in native and transplant kidneys

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Cryoglobulinemic glomerulonephritis in thymic stromal lymphopoietin transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Membranous glomerulonephritis associated with hepatitis C virus infection in renal transplant patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Interferon-alpha treatment of hepatitis C virus-associated mixed cryoglobulinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Response to interferon alpha treatment and disappearance of cryoglobulinaemia in patients infected by hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Sustained response to interferon-alpha or to interferon-alpha plus ribavirin in hepatitis C virus-associated symptomatic mixed cryoglobulinaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Acute exacerbation of vasculitis during interferon-alpha therapy for hepatitis C-associated cryoglobulinaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Effects of ribavirin on hepatitis C-associated nephrotic syndrome in four liver transplant recipients.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Renal failure associated with hepatitis C virus infection. Improvement in renal function after treatment with interferon-alpha.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Interferon treatment on glomerulonephritis associated with hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Interferon versus steroids in patients with hepatitis C virus-associated cryoglobulinaemic glomerulonephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Renal manifestations of hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Response to high-dose interferon-alpha after failure of standard therapy in MPGN associated with hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Membranoproliferative glomerulonephritis associated with hepatitis C virus infection responsive to interferon-alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Interferon-alpha in combination with ribavirin as initial treatment for hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Effect of combination therapy (ribavirin and interferon) in HCV-related glomerulopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Exacerbation of glomerulonephritis in subjects with chronic hepatitis C virus infection after interferon therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Multicenter study of hepatitis C virus infection in chronic hemodialysis patients and hemodialysis center staff members

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Quantitative assessment of HCV load in chronic hemodialysis patients: a cross-sectional survey

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Impact of dialysis room and reuse strategies on the incidence of hepatitis C virus infection in haemodialysis units

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

High incidence of hepatitis C virus infection in hemodialysis patients in Taiwan

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Hepatitis C virus infection in dialysis and renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

National surveillance of dialysis-associated diseases in the United States, 1997.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. The New England Organ Bank Hepatitis C Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Epidemiology of hepatitis C virus infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Hepatitis C virus-induced liver disease in dialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Prevention of hepatitis C virus in dialysis units

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Home hemodialysis protects against hepatitis C virus transmission

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Liver damage in hemodialysis patients with hepatitis C virus viremia: a prospective 10-year study

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Prevalence and risk factors of hepatitis C virus infection in haemodialysis patients: a multicentre study in 2796 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Liver disease patterns in hemodialysis patients with antibodies to hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Hepatitis C virus RNA in anti-HCV positive hemodialyzed patients: significance and therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Comparison of clinical features and liver histology in hepatitis C-positive dialysis patients and renal transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Histopathological features of hepatitis C in renal transplant candidates [see comment]

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Characteristics of hepatitis C in renal transplant candidates.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Risk of death among chronic dialysis patients infected with hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Interferon treatment for chronic hepatitis C virus infection in uremic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Interferon treatment for chronic hepatitis C in haemodialysis patients: suggestions based on a small series

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Efficacy and tolerance of alpha-2b interferon therapy on HCV infection of hemodialyzed patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Interferon treatment for hepatitis C virus infection in patients on haemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

A double-blind controlled trial of recombinant interferon-alpha 2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels. Nephrologists' Group for the Study of HCV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

High rate of hepatitis C virus clearance in hemodialysis patients after interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Limited benefits of INF-alpha therapy in renal graft candidates with chronic viral hepatitis B or C.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Low-dose leukocyte interferon-alpha therapy in dialysed patients with chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Interferon therapy for chronic hepatitis C in hemodialysis patients: increased serum levels of interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Interferon-alpha in chronic hepatitis C infection in dialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Effect of interferon-alpha treatment in hemodialysis patients and renal transplant recipients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

The tolerance and efficacy of interferon‐α in haemodialysis patients with HCV infection: a multicentre, prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Virological and histological responses to one year alpha-interferon-2a in hemodialyzed patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Hepatitis C infection and the patient with end-stage renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Clinical Pharmacokinetics of Interferons

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

The kidney is the main site of interferon degradation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Pharmacokinetics of human and recombinant leukocyte interferon in patients with chronic renal failure who are undergoing hemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection--a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis C: results of a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Impact of hepatitis B and C virus on kidney transplantation outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Hepatitis C virus infection in kidney transplantation and a pilot study of the effects of interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Hepatitis C virus seropositivity at the time of renal transplantation in the United States: associated factors and patient survival

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Management of chronic viral hepatitis before and after renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Hepatitis C virus-associated fibrosing cholestatic hepatitis after renal transplantation: response to interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Quantitation of hepatitis C virus RNA in liver transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Severe evolution of chronic hepatitis C in renal transplantation: a case control study

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Long-term follow-up of hepatitis C virus infection among organ transplant recipients: implications for policies on organ procurement.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Clinicopathological features of rapidly progressive hepatitis C virus infection in HCV antibody negative renal transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Impact of hepatitis C virus duration and hepatitis C virus genotypes on renal transplant patients: correlation with clinicopathological features

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Co-infection by hepatitis B virus and hepatitis C virus in renal transplantation: morbidity and mortality in 1098 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Transmission of hepatitis C virus by organ transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

A prospective study of hepatitis C virus infection in renal allograft recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Hepatitis C virus genotype does not affect patient survival among renal transplant candidates. The New England Organ Bank Hepatitis C Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Longitudinal analysis of hepatitis C virus replication and liver fibrosis progression in renal transplant recipients.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Transplantation of kidneys from donors with hepatitis C antibody into recipients with pre-transplantation anti-HCV.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Changes in hepatitis C virus RNA viremia concentrations in long-term renal transplant patients after introduction of mycophenolate mofetil

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Pretransplant hepatitis C virus infection: a predictor of proteinuria after renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

De novo membranoproliferative glomerulonephritis in hepatitis C virus-infected renal allograft recipients.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Transmission of viral hepatitis by kidney transplantation: donor evaluation and transplant policies (Part 2: hepatitis C virus).

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Screening and confirmatory testing of cadaver organ donors for hepatitis C virus infection: a U.S. National Collaborative Study

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Depletion of hepatitis C virus from procured kidneys using pulsatile perfusion preservation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Shorter waiting times for hepatitis C virus seropositive recipients of cadaveric renal allografts from hepatitis C virus seropositive donors

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Hepatitis C superinfection in hepatitis C virus (HCV)-infected patients transplanted with an HCV-infected kidney.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Policies concerning the use of kidneys from donors infected with hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Hepatitis C infection in cadaver organ donors: strategies to reduce transmission of infection and prevent organ waste

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Glomerulonephritis in renal allografts associated with hepatitis C infection: a possible relationship with transplant glomerulopathy in two cases

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Hepatitis C virus infection and de novo glomerular lesions in renal allografts

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Glomerular disease during HCV infection in renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Proteinuria at five years after kidney transplantation: the role of anti-HCV-positive state

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

High incidence of proteinuria in hepatitis C virus-infected renal transplant recipients is associated with poor patient and graft outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Hepatitis C antibody status and outcomes in renal transplant recipients.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Hepatitis C--associated glomerular disease in liver transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Cryoglobulinemia presenting after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Renal disease in hepatitis C-positive liver transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Nephrotic syndrome after liver transplantation in a patient with hepatitis C virus-associated glomerulonephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Hepatitis-C-associated cryoglobulinemia after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Kidney transplantation for end-stage renal failure in liver transplant recipients with hepatitis C viral infection

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Low-dose recombinant leukocyte interferon-alpha treatment of hepatitis C viral infection in renal transplant recipients. A pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Interferon-alpha-induced acute renal allograft rejection

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Effect of interferon-alfa treatment in renal transplant recipients with chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Outcome of long-term ribavirin therapy for recurrent hepatitis C after liver transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Ribavirin therapy for hepatitis C infection following liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Treatment of hepatitis C virus infection with ribavirin in kidney transplant patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900828-X

7 January 2021

Hepatitis C virus associated membranous glomerulonephritis

42

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(03)00828-X

A lethal course of chronic hepatitis C, glomerulonephritis, and pulmonary vasculitis unresponsive to interferon treatment

16 March 2024

71

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(03)00828-X

Recommendations for preventing transmission of infections among chronic hemodialysis patients

16 March 2024

77

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(03)00828-X

Prevalence of hepatitis C virus-associated mixed cryoglobulinemia after liver transplantation

16 March 2024

167

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(03)00828-X

16 March 2024

Identifiers

1 reference

8 August 2017

1 reference